These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 17317846)

  • 41. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
    Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
    Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRAF mutations in papillary thyroid carcinoma.
    Wojciechowska K; Lewinski A
    Endocr Regul; 2006 Dec; 40(4):129-38. PubMed ID: 17201587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression.
    Kondo T; Zheng L; Liu W; Kurebayashi J; Asa SL; Ezzat S
    Cancer Res; 2007 Jun; 67(11):5461-70. PubMed ID: 17545628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
    Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
    Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
    Sharma A; Tran MA; Liang S; Sharma AK; Amin S; Smith CD; Dong C; Robertson GP
    Cancer Res; 2006 Aug; 66(16):8200-9. PubMed ID: 16912199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
    Guan H; Ji M; Hou P; Liu Z; Wang C; Shan Z; Teng W; Xing M
    Cancer; 2008 Jul; 113(2):247-55. PubMed ID: 18470905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
    Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
    Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
    Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
    Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MEK-ERK signaling plays diverse roles in the regulation of facial chondrogenesis.
    Bobick BE; Kulyk WM
    Exp Cell Res; 2006 Apr; 312(7):1079-92. PubMed ID: 16457813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
    Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
    Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
    Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.
    Zerilli M; Zito G; Martorana A; Pitrone M; Cabibi D; Cappello F; Giordano C; Rodolico V
    Mod Pathol; 2010 Aug; 23(8):1052-60. PubMed ID: 20473281
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
    Riesco-Eizaguirre G; Gutiérrez-Martínez P; García-Cabezas MA; Nistal M; Santisteban P
    Endocr Relat Cancer; 2006 Mar; 13(1):257-69. PubMed ID: 16601293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
    Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
    Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.